icon-folder.gif   Conference Reports for NATAP  
 
  64rd Annual Meeting of the
American Association for the
Study of Liver Diseases
Washington, DC Nov 1-5 2013
Back grey_arrow_rt.gif
 
 
 
Abbvie at AASLD
 
 
  AASLD: Safety of Ribavirin-containing Regimens of ABT-450/r, ABT-333, and ABT-267 for the Treatment of HCV Genotype 1 Infection and Efficacy in Subjects With Ribavirin Dose Reductions - (11/06/13)
 
AASLD: High Medication Adherence in HCV-Infected Patients Taking a Triple-DAA Regimen for 12 Weeks - (11/06/13)
 
AASLD: Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 With SVR24 After Treatment With ABT-450/r, ABT-267, ABT-333 + Ribavirin in Patients With Chronic HCV Genotype 1 Infection in the AVIATOR Study - (11/06/13)
 
AASLD: Interferon- and Ribavirin-free Regimen of ABT-450/r + ABT-267 in HCV Genotype 1b-infected Treatment-na´ve Patients and Prior Null Responders - (11/04/13)
 
64rd Annual Meeting of the American Association for the Study of Liver Diseases Washington, DC Nov 1-5 2013
 
SAFETY AND EFFICACY OF INTERFERON-FREE REGIMENS OF ABT-450/r, ABT-267, ABT-333 +/- RIBAVIRIN IN PATIENTS WITH CHRONIC HCV GT1 INFECTION: RESULTS FROM THE AVIATOR STUDY - (04/25/13)

rep.png